Skip to main content
Equibles

ROYAL BANK OF CANADA

Bank

Position in ABBV — AbbVie Inc.

CIK 1000275 TORONTO, A6
Back to ABBV Full portfolio

Position in ABBV

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$2,054,340,133
+$415,738,293 QoQ
Shares Held
8,163,806
+8.4% QoQ
Ownership
0.462%
of shares outstanding
% of Portfolio
0.41%
of 13F equity value
Holder Rank
#31
of 4,152 holders
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 98% Shared 0% None 2%

Common Shares in ABBV Over Time

Shares Held

Position Value (USD)

Derivatives in ABBV

reported options exposure · as of Jun 30, 2026
CallValue
$95,623,200
CallShares
380,000
PutValue
$780,084
PutShares
3,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

ROYAL BANK OF CANADA holds $19,128,320,487 across 19 Drug Manufacturers - General names. ABBV ranks #3 (10.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 4,358,401 $5,227,597,337
2 JNJ
Johnson & Johnson
 13,211,475 $3,355,318,297
3 ABBV
AbbVie Inc.
This page 		8,163,806 $2,054,340,133
4 AZN
Astrazeneca PLC
 10,427,503 $1,977,263,112
5 MRK
Merck & Co., Inc.
 14,293,086 $1,836,661,547
6 AMGN
Amgen Inc
 4,328,785 $1,567,539,618
7 PFE
Pfizer Inc
 32,814,260 $790,167,373
8 BMY
Bristol Myers Squibb Co
 12,094,886 $696,907,326

All Filings in ABBV

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $95,623,200 380,000
2026-06-30 $780,084 3,100
2026-06-30 $2,054,340,133 8,163,806
2026-03-31 $92,433,250 425,000
2026-03-31 $1,638,601,840 7,534,148
2026-03-31 $6,568,198 30,200
2025-12-31 $1,802,756,159 7,889,869
2025-12-31 $68,844,037 301,300
2025-09-30 $156,081,114 674,100
2025-09-30 $1,936,159,702 8,362,096
2025-06-30 $1,720,041,597 9,266,467
2025-06-30 $74,248,000 400,000
2025-03-31 $1,850,153,154 8,830,437
2025-03-31 $204,491,520 976,000
2025-03-31 $2,933,280 14,000
2024-12-31 $3,554,000 20,000
2024-12-31 $1,549,639,951 8,720,540
2024-12-31 $17,770,000 100,000
2024-09-30 $1,750,718,647 8,865,296
2024-09-30 $3,949,600 20,000
2024-06-30 $1,479,651,407 8,626,699
2024-06-30 $3,430,400 20,000
2024-03-31 $3,642,000 20,000
2024-03-31 $1,481,394,418 8,135,060
2023-12-31 $1,358,010,469 8,763,054
2023-12-31 $3,145,891 20,300
2023-12-31 $7,035,638 45,400
2023-09-30 $1,378,748,050 9,249,618
2023-09-30 $3,025,918 20,300
2023-06-30 $2,735,019 20,300
2023-06-30 $1,233,774,337 9,157,384
2023-03-31 $1,547,612,260 9,710,813
2023-03-31 $47,811 300
2022-12-31 $6,028,053 37,300
2022-12-31 $1,579,926,340 9,776,167
2022-09-30 $2,321,833 17,300
2022-09-30 $1,224,138,930 9,121,071
2022-09-30 $60,931,340 454,000
2022-06-30 $1,455,702,782 9,504,458
2022-06-30 $2,603,720 17,000
2022-03-31 $1,494,055,519 9,216,307
2022-03-31 $2,755,870 17,000
2021-12-31 $24,588,640 181,600
2021-12-31 $1,409,117,135 10,407,069
2021-09-30 $1,076,393,515 9,978,618
2021-09-30 $19,589,192 181,600
2021-09-30 $1,294,440 12,000
2021-06-30 $5,632,000 50,000
2021-06-30 $33,837,056 300,400
2021-06-30 $1,118,973,523 9,934,069

Report a Problem

Category
Description
Email (optional, for follow-up)